![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessAdjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data
Daratumumab plus lenalidomide and dexamethasone (D-Rd) and bortezomib plus lenalidomide and dexamethasone (VRd) are commonly used treatment combinations for transplant-ineligible (TIE) patients with newly diag...
-
Article
Open AccessImpact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry
Maintenance therapy after autologous stem cell transplantation (ASCT) is recommended for use in multiple myeloma (MM); however, more data are needed on its impact on health-related quality of life (HRQoL). Pre...
-
Article
Observational study of multiple myeloma in Latin America
Relatively little is known about the outcomes of multiple myeloma in Latin America, a world region where incorporation of novel agents is generally slow. In the current retrospective-prospective study, we aime...
-
Article
Awareness, concern, and communication between physicians and patients on bone health in cancer
This study aims to explore physician–patient communications about bone metastases and cancer treatment-induced bone loss (CTIBL).
-
Chapter
The Role of Anatomic and Functional Imaging in Myeloma
-
Article
Phase II evaluation of bisantrene in refractory multiple myeloma
-
Chapter
Workshop on growth factors
The ‘Workshop on Growth Factors’ which took place at the Lugano Lymphoma Conference on June 8, 1990, included a presentation by Michael Sporn on the concept that loss of inhibitory control mechanisms may be im...
-
Chapter and Conference Paper
Cytogenetic Abnormalities in Multiple Myeloma
Cytogenic studies in multiple myeloma have been very difficult because of the predominantly low proliferative activity in this disease (1-7). In the series reported to date the most commonly affected chromosomes ...
-
Chapter
Macrophages as an Important Source of Paracrine IL6 in Myeloma Bone Marrow
Interleukin 6 (IL6) is a pleiotropic cytokine which has been shown to be a very potent growth factor for myeloma cells, particularly cells derived from patients with aggressive clinical disease (1,2). Although it...
-
Article
DANAZOL-INDUCED FACTOR IX AND VIII BYPASSING ACTIVITY
Danazol, a synthetic androgen reported to increase factor VIII and IX activity levels, was given to 5 hemophiliacs who were >17 years old (3 with severe hemophilia A, one moderate hemophilia A and one moderate...
-
Article
EFFECT OF DANAZOL ON APTT, COAGULANT FACTOR ACTIVITY AND BLEEDING IN HEMOPHILIA
Danazol has been reported to raise several plasma proteins. Danazol was given orally at 600 mg/day in 3 divided doses to 6 hemophiliacs for 8-14 weeks. Factor levels, APTT and other laboratory parameters were ...
-
Article
Treatment of patients with refractory myelogenous leukemia with BCOMM [1,3-bis-chloro(2-chloroethyl)-1-nitrosourea (BCNU), oncovin (vincristine), cyclophosphamide, high-dose methotrexate and methyl-glyoxal bis-guanylhydrazone (MGBG)]
Ten patients with AML refractory to anthracyclines and cytosine arabinoside were treated with vincristine 1.4 mg/m2 and methotrexate (MTX) 2.5 gm/m2 by intravenous (IV) bolus on day 1 [citrovorum factor (CF) resc...
-
Article
Quantitative association between the in vitro human tumor stem cell assay and clinical response to cancer chemotherapy
Objective methods have been developed to quantitate results of the in vitro human tumor stem cell assay, the degree of the association between the in vitro assay and clinical response as well as the likelihood...
-
Article
Altered Polyamine Metabolism in Cystic Fibrosis
Summary: Children with cystic fibrosis excreted elevated urinary levels of all three polyamines—putrescine, spermidine, and spermine. Heterozygote parents excreted intermediate concentrations of the polyamines...